190 related articles for article (PubMed ID: 27375788)
1. Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep).
Ngambenjawong C; Gustafson HH; Pineda JM; Kacherovsky NA; Cieslewicz M; Pun SH
Theranostics; 2016; 6(9):1403-14. PubMed ID: 27375788
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
3. Engineering an Affinity-Enhanced Peptide through Optimization of Cyclization Chemistry.
Ngambenjawong C; Pineda JM; Pun SH
Bioconjug Chem; 2016 Dec; 27(12):2854-2862. PubMed ID: 27779387
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of tumor associated macrophages in different tumor models.
Kakoschky B; Pleli T; Schmithals C; Zeuzem S; Brüne B; Vogl TJ; Korf HW; Weigert A; Piiper A
PLoS One; 2018; 13(2):e0193015. PubMed ID: 29447241
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
Cieslewicz M; Tang J; Yu JL; Cao H; Zavaljevski M; Motoyama K; Lieber A; Raines EW; Pun SH
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15919-24. PubMed ID: 24046373
[TBL] [Abstract][Full Text] [Related]
6. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.
Pang L; Pei Y; Uzunalli G; Hyun H; Lyle LT; Yeo Y
Pharm Res; 2019 Mar; 36(4):65. PubMed ID: 30859335
[TBL] [Abstract][Full Text] [Related]
7. Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth.
Shan H; Dou W; Zhang Y; Qi M
Nanoscale; 2020 Nov; 12(43):22268-22280. PubMed ID: 33146206
[TBL] [Abstract][Full Text] [Related]
8. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
9. Peptide-Based [
Huang M; Wang R; Li M; Cai H; Tian R
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432702
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
11. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
12. Multivalent polymers displaying M2 macrophage-targeting peptides improve target binding avidity and serum stability.
Ngambenjawong C; Pun SH
ACS Biomater Sci Eng; 2017 Sep; 3(9):2050-2053. PubMed ID: 29430522
[TBL] [Abstract][Full Text] [Related]
13. Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide.
Lepland A; Asciutto EK; Malfanti A; Simón-Gracia L; Sidorenko V; Vicent MJ; Teesalu T; Scodeller P
Mol Pharm; 2020 Jul; 17(7):2518-2531. PubMed ID: 32421341
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
16. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract][Full Text] [Related]
17. Bio-Responsive nanoparticle for tumor targeting and enhanced photo-immunotherapy.
Tian D; Qin F; Zhao H; Zhang C; Wang H; Liu N; Ai Y
Colloids Surf B Biointerfaces; 2021 Jun; 202():111681. PubMed ID: 33714187
[TBL] [Abstract][Full Text] [Related]
18. Reversibly Switchable, pH-Dependent Peptide Ligand Binding via 3,5-Diiodotyrosine Substitutions.
Ngambenjawong C; Sylvestre M; Gustafson HH; Pineda JMB; Pun SH
ACS Chem Biol; 2018 Apr; 13(4):995-1002. PubMed ID: 29481044
[TBL] [Abstract][Full Text] [Related]
19. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
20. TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
Lee C; Kim S; Jeong C; Cho I; Jo J; Han IH; Bae H
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
